AKTX Akari Therapeutics PLC: ערך חשבונאי למניה

Akari Therapeutics (AKTX) is a recognized expert in the therapy of rare blood pathologies, developing effective complement inhibitors. The book value per share trend illustrates current asset capitalization, where 10.61 expresses today's metric value. The robotization of laboratory tests accelerates the search for formulas, however, a high cash burn rate and post-merger complexities create significant financial risks.

For Akari Therapeutics (AKTX), which is focused on costly clinical trials without current revenue, the book value per share serves as a key indicator of financial stability. This metric reflects the value of net assets minus liabilities, defining the business's actual tangible base and creating a defensive floor for investors during periods of high price volatility.